Relamorelin

Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research[1][2][3][4].

Product Specifications

CAS Number

[661472-41-9]

Product Name Alternative

RM-131; BIM-28131

UNSPSC

12352209

Target

GHSR

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/relamorelin.html

Solubility

10 mM in DMSO

Smiles

O=C(C1CCNCC1)N[C@H](CC2=CSC3=CC=CC=C23)C(N[C@@H](C(N[C@@H](CC4=CC=CC=C4)C(NC5(CCNCC5)C(N)=O)=O)=O)CC6=CNC7=CC=CC=C67)=O

Molecular Formula

C43H50N8O5S

Molecular Weight

790.97

References & Citations

[1]DeBoer MD, et, al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007 Jun;148 (6) :3004-12.|[2]Fischer K, et, al. The Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin Receptor. Front Nutr. 2015 Jan 12;1:31.|[3]Zatorski H, et, al. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. J Physiol Pharmacol. 2017 Dec;68 (6) :797-805.|[4]Matthew Heckroth, et al. Nausea and Vomiting in 2021: A Comprehensive Update. J Clin Gastroenterol. 2021 Apr 1;55 (4) :279-299.|[5]Victor Chedid, et al. Relamorelin for the treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2017 Oct;26 (10) :1189-1197.